Gene to Health Limited primarily focuses on developing multi-omics predictive models for common disease risks, conducting biomedical big data analysis and modeling, and providing bioinformatics research services.  We are a pioneer in Asia focused on polygenic scoring technology, leveraging millions of disease-related genetic variants and other omics data to predict over 1000 traits and diseases. Our core product suite, G2H, provides personalized health management solutions in one platform, including risk assessments for chronic diseases, dietary optimization, lifestyle advisory, and cancer risk prediction. We aim to revolutionize disease prevention and improve early disease intervention by integrating advanced genomic analysis, ML and AI.

我们是来自香港大学医学院 (HKU Med) 的博士创业团队，拥有以Polygenic Scoring （多基因风险评分，PGS）的核心技术，基因智健（G2H）平台是我们开发的核心产品。该平台主要利用基于多组学大数据的统计机器学习模型分析用户数据，从而预测和评估上千种种人类疾病风险和健康表型，为您的健康人生保驾护航。